CK1\(\varepsilon\) is Required for Breast Cancers Dependent on \(\beta\)-Catenin Activity

DSpace/Manakin Repository

CK1\(\varepsilon\) is Required for Breast Cancers Dependent on \(\beta\)-Catenin Activity

Citable link to this page

 

 
Title: CK1\(\varepsilon\) is Required for Breast Cancers Dependent on \(\beta\)-Catenin Activity
Author: Firestein, Ron; Gupta, Piyush; Repich, Kara; Silver, Serena J.; Boehm, Jesse S.; Kim, So Young; Dunn, Ian Frederick; Wardwell, Leslie; Schinzel, Anna; Wittner, Ben; Root, David E.; Ramaswamy, Sridhar; Lander, Eric Steven; Hahn, William C.

Note: Order does not necessarily reflect citation order of authors.

Citation: Kim, So Young, Ian F. Dunn, Ron Firestein, Piyush Gupta, Leslie Wardwell, Kara Repich, Anna C. Schinzel, et al. 2010. CK1\(\varepsilon\) is required for breast cancers dependent on \(\beta\)-catenin activity. PLoS ONE 5(2): e8979.
Full Text & Related Files:
Abstract: Background: Aberrant \(\beta\)-catenin signaling plays a key role in several cancer types, notably colon, liver and breast cancer. However approaches to modulate \(\beta\)-catenin activity for therapeutic purposes have proven elusive to date. Methodology: To uncover genetic dependencies in breast cancer cells that harbor active \(\beta\)-catenin signaling, we performed RNAi-based loss-of-function screens in breast cancer cell lines in which we had characterized \(\beta\)-catenin activity. Here we identify CSNK1E, the gene encoding casein kinase 1 epsilon (CK1\(\varepsilon\)) as required specifically for the proliferation of breast cancer cells with activated \(\beta\)-catenin and confirm its role as a positive regulator of \(\beta\)-catenin-driven transcription. Furthermore, we demonstrate that breast cancer cells that harbor activated \(\beta\)-catenin activity exhibit enhanced sensitivity to pharmacological blockade of Wnt/\(\beta\)-catenin signaling. We also find that expression of CK1\(\varepsilon\) is able to promote oncogenic transformation of human cells in a \(\beta\)-catenin-dependent manner. Conclusions/Significance: These studies identify CK1\(\varepsilon\) as a critical contributor to activated \(\beta\)-catenin signaling in cancer and suggest it may provide a potential therapeutic target for cancers that harbor active \(\beta\)-catenin. More generally, these observations delineate an approach that can be used to identify druggable synthetic lethal interactions with signaling pathways that are frequently activated in cancer but are difficult to target with the currently available small molecule inhibitors.
Published Version: doi://10.1371/journal.pone.0008979
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813871/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10198945
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters